A Phase 3 interventional study of Comparator: Sitagliptin phosphate and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 44th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 58th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 395 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 59th largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 86 in phase 3, and was the 67th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Comparator: Sitagliptin phosphate
Drug: Comparator: Placebo
All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
Also known as: GLUCOPHAGE®
All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
Also known as: GLUCOPHAGE®
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 24
Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
Time frame: Baseline and Week 24
| Milestone | Sitagliptin | Placebo |
|---|---|---|
| Started | 197 | 198 |
| Completed | 174 | 182 |
| Not completed | 23 | 16 |
| Withdrew: Clinical adverse event | 9 | 3 |
| Withdrew: Laboratory adverse event | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Other reason | 2 | 2 |
| Withdrew: Protocol violation | 3 | 2 |
| Withdrew: Subject moved | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
| Percent | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 24 | -1.02 ± 0.99 | -0.14 ± 1.22 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
| Percent | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1000 mg/Day | -0.84 ± 1.09 | -0.01 ± 1.31 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
| Percent | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 24 for Participants on Metformin 1700 mg/Day | -1.14 ± 0.88 | -0.21 ± 1.12 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
| mg/dL | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 | -43.4 ± 57.3 | -10.0 ± 60.0 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0.
| mg/dL | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -20.3 ± 39.1 | 0.5 ± 40.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 7/197 (3.6%) | 10/197 (5.1%) |
| Placebo | — | 5/198 (2.5%) | 13/198 (6.6%) |
| Event | Sitagliptin | Placebo |
|---|---|---|
| CEREBRAL INFARCTIONNervous system disorders | 2/197 | 0/198 |
| POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications | 1/197 | 0/198 |
| DIABETES MELLITUSMetabolism and nutrition disorders | 1/197 | 0/198 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 1/197 | 0/198 |
| LIP AND/OR ORAL CAVITY CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/197 | 0/198 |
| IIIrd NERVE PARALYSISNervous system disorders | 1/197 | 0/198 |
| EPIGLOTTIC CYSTRespiratory, thoracic and mediastinal disorders | 1/197 | 0/198 |
| SPINAL CORD INJURY CERVICALInjury, poisoning and procedural complications | 0/197 | 1/198 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 0/197 | 1/198 |
| TENOSYNOVITISMusculoskeletal and connective tissue disorders | 0/197 | 1/198 |
| Event | Sitagliptin | Placebo |
|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 10/197 | 13/198 |
| Age, Continuous(years) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 54.1 ± 9.0 | 55.1 ± 9.8 | 54.6 ± 9.4 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Female | 105 | 90 | 195 |
| Male | 92 | 108 | 200 |
| Region of Enrollment(participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| China | 197 | 198 | 395 |
| Hemoglobin A1c (HbA1c)(Percent) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 8.5 ± 0.9 | 8.5 ± 0.9 | 8.5 ± 0.9 |
| 2-hour Post-meal Glucose(mg/dL) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 258.0 ± 58.0 | 258.7 ± 63.2 | 258.3 ± 60.6 |
| Fasting Plasma Glucose(mg/dL) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 173.4 ± 39.3 | 173.9 ± 40.0 | 173.7 ± 39.6 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Dec 2008 to primary completion in Aug 2010, 20 months.
Results were first posted in Sep 2011, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin